VEGFR-2/DHFR-IN-2 (compound 5b) is a dual inhibitor targeting VEGFR-2 and DHFR, with respective IC50 values of 0.623 μM and 9.085 μM. It demonstrates potent cytotoxicity against C26, HepG2, and MCF7 cancer cell lines, with IC50 values ranging from 3.59 μM to 8.38 μM. VEGFR-2/DHFR-IN-2 holds promise for cancer research [1].

VEGFR-2/DHFR-IN-2 (2-1024 μg/mL; 18-72 h) shows antibacterial and antifungal activities with MIC values of 64, 64, 32, 32, 16, 32, 64 and 256 μg/mL for Escherichia coli, Pseudomonas aeruginosa, Streptococcus faecalis, Salmonella enterica, MSSA, MRSA, Candida albicans and Aspergillus niger, respectively [1]. VEGFR-2/DHFR-IN-2 (0.5-100 μM; 48 h) exhibits anticancer activities [1]. VEGFR-2/DHFR-IN-2 (0-100 μM; 30 min) shows DHFR and VEGFR-2 inhibitory activities with IC 50 s of 9.085 and 0.623 μM, respectively [1]. Cell Cytotoxicity Assay [1] Cell Line: C26, HepG2, MCF7 and H69PR cell lines Concentration: 0.5, 1, 5, 10, 25, 50, 80 and 100 μM Incubation Time: 48 hours Result: Showed anticancer activities to C26, HepG2, MCF7 and H69PR cells with IC 50 s of 3.59, 8.38, 6.75 and 28.45 μM, respectively.